URGNUroGen Pharma Ltd.

$927M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M+11.9% YoY

Gross Profit

$16M87.5% margin

Operating Income

-$20M-112.1% margin

Net Income

-$29M-159.6% margin

EPS (Diluted)

$-1.22

QoQ Revenue Growth

+12.4%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$21M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$136M

Total Liabilities

$225M

Stockholders' Equity

-$89M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$16M	+11.9%
Gross Profit	$16M	$15M	+8.5%
Operating Income	-$20M	-$20M	-1.8%
Net Income	-$29M	-$28M	-1.5%

Revenue Segments

Jelmyto

$18M100%

URGN Q4 2022 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena